Article Details

Empyrean Grabs $22M to Target CNS Disorders with Plant-Based Platform | BioSpace

Retrieved on: 2022-10-18 19:13:25

Tags for this article:

Click the tags to see associated articles and topics

Empyrean Grabs $22M to Target CNS Disorders with Plant-Based Platform | BioSpace. View article details on hiswai:

Excerpt

Genetic engineering company Empyrean Neurosciences stepped into the CNS arena with $22 million and a small molecule platform derived from plants ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up